OPTI SARS-CoV-2/Influenza A/B RT-PCR Test (99-57014) for identification and differentiation of SARS-CoV-2, influenza A, and influenza B RNA - 500 reactions kit box and vials

OPTI SARS-CoV-2/Influenza A/B            RT-PCR Test

OPTI Medical Systems has obtained CE marking for its OPTI SARS-CoV-2/Influenza A/B RT-PCR Test for identification and differentiation of SARS-CoV-2, influenza A, and influenza B RNA. The test is available in countries accepting the CE mark.

This respiratory panel distinguishes between SARS-CoV-2 and influenza A and B extracted from nasopharyngeal swabs. Use of this test is ideal for identifying the cause of symptoms during influenza season.

Contact us

Distinguish between COVID-19 and flu

  • Multiplexed detection and differentiation of three viruses simultaneously.
  • Detection of two different targets in the N coding region of SARS-CoV-2, avoiding the S mutations found in recent variants.
  • Monitoring of new variants of SARS-CoV-2 to ensure the test is not impacted by viral mutations.
  • Optimized workflow from start to finish using an internal sample control targeting human RNase P.
  • Secure supply in an uncertain situation.
  • Combine this test with the OPTI DNA/RNA Magnetic Bead Kit for a complete solution.



The OPTI SARS-COV-2/Influenza A/B RT-PCR Test delivers highly accurate results with high sensitivity (LoD ≤3 copies/μl). Results are available as fast as 2 hours, including RNA extraction. The test detects SARS-CoV-2 variants of concern based on the sequences submitted to the GISAID database.

IDEXX Laboratories, the parent of OPTI Medical Systems, has extensive expertise in PCR test development and manufacturing.


OPTI DNA/RNA Magnetic Bead Kit

The OPTI DNA/RNA Magnetic Bead Kit is intended for extracting RNA from respiratory samples for subsequent analysis with the OPTI SARS-CoV-2/Influenza A/B RT-PCR Test. The extraction kit requires minimum hands-on time (less than 15 minutes) when used on automated magnetic separators, such as Kingfisher™ purification systems, for high-throughput sample processing. The optional manual protocol minimizes instrument investments.

Contact information for inquiries related to COVID-19

COVID-19 test availability

[email protected]


IDEXX investor resources

[email protected]

Media inquiries

[email protected]


COVID-19 resources

COVID-19 resources


This CE mark certification represents OPTI Medical Systems’ assurance that its test complies with the European Union’s In Vitro Diagnostic Medical Devices Directive, which applies to products that are manufactured in or designed to be sold in the European Economic Area* and Switzerland.

This test has not been reviewed by the FDA.

*The European Economic Area includes the European Union (Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden) and the following countries: Iceland, Liechtenstein, Norway, and United Kingdom.